Using a Closed-loop System for Oxygen Delivery (FreeO2) to Optimize Oxygentherapy in Patients With COPD Exacerbation

NCT ID: NCT01393015

Last Updated: 2011-07-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-07-31

Study Completion Date

2011-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Aim: The purpose of this study is to evaluate the use feasibility of FreeO2 so as to deliver automatically oxygen and to enable a remote medical monitoring with a homogeneous patient population hospitalize for Chronic obstructive pulmonary disease (COPD)exacerbation.

Hypothesis: The principal hypothesis is that FreeO2 is possible and well-accepted by nurses and medical personnel and there are advantages to use this system. In comparison with the common oxygen delivery (the rotameter), the hypothesis is that FreeO2 system will make for a better control of the oxygen saturation in function of designed target, reducing the desaturation time and hyperoxia. We think that oxygen weaning will be faster than classical way if it is automated. In addition, FreeO2 could reduce the number of intervention by nurse personnel and to improve the support with centralized monitoring in the FreeO2 group.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COPD Exacerbation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

FreeO2 system

FreeO2 is a new system that automatically adjusts the oxygen flow delivered to patients in closed-loop based on the SpO2 signal. This system is intended to maintain SpO2 in a predefined target and to adapt oxygen flow to patient's needs.

Group Type EXPERIMENTAL

Automated settings on the oxygen delivery device

Intervention Type DEVICE

FreeO2 automatically adjusts the oxygen flow delivered to patients based on the SpO2 signal. Patients keep using the same device for duration of hospitalization.

Rotameter (flowmeter)

A rotameter is a device that measures the flow rate of liquid or gas in a closed tube.

Group Type ACTIVE_COMPARATOR

Manual settings with FreeO2 system in collection mode

Intervention Type DEVICE

Oxygen flow delivery is adjust by nurse and respiratory therapists. Standard medical treatment. Patients keep using the same device for duration of hospitalization.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Automated settings on the oxygen delivery device

FreeO2 automatically adjusts the oxygen flow delivered to patients based on the SpO2 signal. Patients keep using the same device for duration of hospitalization.

Intervention Type DEVICE

Manual settings with FreeO2 system in collection mode

Oxygen flow delivery is adjust by nurse and respiratory therapists. Standard medical treatment. Patients keep using the same device for duration of hospitalization.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient hospitalized for COPD exacerbation
* 40 Years and older
* Former or current smoker greater than or equal to 10 pack-years
* Suspicion or diagnosis of COPD at the hospitalisation
* Acute dyspnea or acute aggravation of dyspnea
* Respiratory rate greater than or equal to 20 breaths/min
* Patient needs an oxygen therapy by nasal cannula with oxygen delivered between 0.5 to 8L/min to hold SpO2 greater than or equal to 92%

Exclusion Criteria

* Imminent indications for intubation
* FreeO2 system is unavailable at the moment of randomization
* Patient in isolation (barrier nursing) to the inclusion
* Patient participates to another clinical trial without possibility of co-enrollment
* Patient with diagnosis of sleep apnea
Minimum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

CRIUCPQ

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

François Lellouche, Md

Role: PRINCIPAL_INVESTIGATOR

Institut universitaire de cardiologie et de pneumologie de Québec, University Laval

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Centre de recherche de l'institut universitaire de cardiologie et de pneumologie de Québec

Québec, Quebec, Canada

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Canada

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Pierre-Alexandre Bouchard, inh

Role: CONTACT

1 418 656-8711 ext. 2712

Maude Roberge

Role: CONTACT

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Pierre-Alexandre Bouchard, inh

Role: primary

1-418-656-8711 ext. 2712

Maude Roberge

Role: backup

References

Explore related publications, articles, or registry entries linked to this study.

Poder TG, Kouakou CRC, Bouchard PA, Tremblay V, Blais S, Maltais F, Lellouche F. Cost-effectiveness of FreeO2 in patients with chronic obstructive pulmonary disease hospitalised for acute exacerbations: analysis of a pilot study in Quebec. BMJ Open. 2018 Jan 23;8(1):e018835. doi: 10.1136/bmjopen-2017-018835.

Reference Type DERIVED
PMID: 29362258 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

FreeO2-COPD-5ePC

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.